Exposure of adipocytes to antibodies to the insulin receptor results in a blockade of 125I-labeled insulin binding, stimulation of glucose oxidation, and many more insulin-like effects. Allowing for differences in purity, antireceptor antibody is equipotent with insulin on a molar basis. Both the bivalent F(ab')2 and monovalent Fab' fragments of the antireceptor antibody are fully active in inhibiting 25I-labeled insulin binding. Bivalent F(ab')% also retains its insulin-like effects.
In contrast, the monovalent Fab' loses almost all ability to stimulate glucose oxidation and acts as a competitive antagonist of insulin-stimulated lucose oxidation. Addition of anti-F(ab')2 antisera, which cross ink the Fab'-receptor complexes, results in a restoration of the insulin-like activity of the antibody. Similarly, when cells are exposed to submaximal doses of insulin, addition of anti-insulin antibodies at low concentration enhances the biological activity of insulin. These data suggest that receptor occupancy by ligand is not sufficient for signal generation and that the insulin-like effects of antireceptor antibody (and perhaps insulin itself) require receptor aggregation or clustering. This aggregation, however, appears to be independent of microfilaments or microtubules -because the insulin-like effects of antireceptor antibody, and in fact, of insulin itself, are unaffected by agents that are known to disrupt these structures.
The first step in insulin action is binding to a receptor site on the plasma membrane of the cell (1) . Exactly how this interaction of the hormone with its receptor is transformed into a transmembrane message, however, remains unknown. Most attention has focused on the possibility that the interaction of insulin with its receptor activates some membrane-associated enzyme or transport system, which in turn generates a second intracellular messenger of hormone action, perhaps analogous to cyclic AMP (2) . Recently, several investigators have presented data that insulin or one of its degradation fragments may actually enter the cell (3) (4) (5) , and these workers have postulated that this entry may be important for some of insulin's biological effects.
The discovery of autoantibodies to the insulin receptor in some patients with insulin-resistant diabetes has made available a new tool for the study of insulin action (6, 7) . We have shown that these antibodies will bind to the insulin receptor (8) , block insulin binding (9, 10) , and initiate many of insulin's biological effects (10, 11) . In the present study we have prepared monovalent fragments of these antireceptor antibodies and compared their effects to those of the bivalent antibody. Like the bivalent antibody, monovalent antireceptor antibodies compete for insulin binding to the receptor. The monovalent antibodies, however, are unable to initiate a biological response, and behave as a competitive antagonist of insulin action at the receptor level. The insulin-like activity of the monovalent antireceptor antibody can be restored by addition of a second antibody to crosslink the Fab'-receptor complexes. In addition, the activity of insulin itself is enhanced by crosslinking with anti-insulin antibody. These data provide a direct demonstration of a competitive antagonist of insulin action at the receptor level and suggest that receptor crosslinking or aggregation is important for insulin action.
MATERIALS AND METHODS
Materials. Porcine insulin (lot 7GUHSL) was purchased from Elanco Company, bovine serum albumin (Fraction V, Lot N53309) from Armour and Company, and crude collagenase (CLS45K137) and pepsin (2682 U/mg; lot PM35B735) from Worthington Biochemical Corporation. Cytochalasins B and D and colchicine were purchased from Aldrich Chemical Company, vincristine and vinblastine from Eli Lilly Company, and dinonylphthalate from Eastman Chemical Company. 125I-labeled insulin (125I-insulin) was prepared by a modification of the chloramine-T method (12) at specific activities of 100-200 AiCi/Aig.
The IgG fraction of serum from the patient with the highest concentration of antireceptor antibody activity (B-2) was prepared from the ammonium sulfate precipitate by ion exchange chromatography of DEAE-cellulose (7, 8) . Bivalent F(ab')2 fragment was prepared from the IgG by pepsin digestion (13) and purified by gel filtration on Sephadex G-200. To prepare monovalent Fab' fragments (14) , the F(ab')2 was concentrated and adjusted to pH 8.6 Binding Studies and Glucose Oxidation Bioassay. Isolated adipocytes were prepared from epididymal fat pads of 100-160 gm Sprague-Dawley rats as described by Rodbell (15) . Unless otherwise noted, all studies of 125I-insulin binding were performed in the Krebs-Ringer buffer with albumin, pH 7.4 at 370C as described (10, 15 Fig. 1 shows the effects of the purified IgG fraction and bivalent F(ab')2 and monovalent Fab' fragments of antireceptor antibodies on both the insulin binding and glucose oxidation by isolated adipocytes. All three preparations were able to inhibit 125I-insulin binding and were approximately equipotent in this effect. Significant inhibition of binding was observed with concentrations as low as 1 ,ug/ml. As we have previously reported (10), both the purified IgG and the F(ab')2 fragment also produced insulin-like bioeffects in these cells. In both cases significant stimulation of glucose oxidation was observed at 0.3 jig/ml. Based on our earlier studies (8) which showed that approximately 1% of the total IgG are antireceptor antibodies, the antireceptor antibody is approximately equipotent with insulin on a molar basis in both binding inhibition and bioactivity.
RESULTS
By contrast, the monovalent Fab' has little insulin-like effect on the adipocyte. Thus at 5 jig/ml, a concentration at which bivalent F(ab')2 produces full stimulation of glucose oxidation, the monovalent Fab' produces only about 5% stimulation. At higher concentrations of Fab', some stimulation of glucose oxidation does occur. This is probably due to a small contamination of the preparation with F(ab')2 fragments that have not been successfully reduced. In three different preparations of monovalent Fab' fragments, the insulin-like bioactivity varied from 1% to <0.01% of that of the bivalent antibody. The finding that the monovalent Fab' fragments block insulin binding although possessing little bioactivity suggested that the monovalent Fab' may be able to serve as a competitive antagonist of insulin at the receptor level, and this was confirmed by studying the effect of the Fab' fragment on insulin-stimulated glucose oxidation. When cells pretreated with Fab' at 10 ,ug/ml were subjected to further stimulation by insulin, the dose-response of glucose oxidation was clearly shifted to the right ( (1.5 ng/ml), F(ab')2 (5 gg/ml), or Fab' (5 yg/ml) for 30*nin at 220C. Anti-Fab2 serum was then added at the indicated dilutions to some of the flasks containing buffer or the Fab' fragments. Glucose oxidation was then measured for 1 hr. Anti-F(ab')2 serum alone had no effect on glucose oxidation at any of the concentrations used. Bars:
A, basal; B, insulin at 1.5 ng/ml; C, F(ab')2 at 5 ug/ml; D, Fab' at 5 iAg/ml; E, F, G, and H, Fab' plus anti-F(ab')2 at 1:1000, 1:200, 1:50, and 1:20, respectively. restoration of the bioactivity of the monovalent antibody fragment. At a dilution of 1:50 of the second antibody, the effect of the monovalent Fab' reached a maximum, which was about 60% of the effect that was observed with the F(ab')2. At none of the concentrations tested did anti-F(ab')2 serum alone produce any insulin-like effects.
In an attempt to see if this effect of ligand crosslinking was a general factor in insulin action, experiments were performed in which the effect of anti-insulin antibodies in insulin action was studied. In these experiments, cells were exposed first to a concentration of insulin that produces a submaximal stimulation of glucose oxidation (0.2-0.3 ng/ml) and then anti-insulin antibodies were added at highldilution in hopes of crosslinking some of the insulin bound to the receptors on the cell. Consistent with the effects of anti-F(ab')2 serum on Fab', low concentrations of anti-insulin serum enhanced the activity of these submaximal concentrations of insulin by about 30% (Fig. 4) . Although the effect is small, it was highly reproducible and clearly significant (p < 0.05). The loss of the potentiating effect that occurs as the antibody concentration is increased could be simply due to the fact that the antibodies bind free insulin in solution and thus decrease its concentration or due to the fact that the antibody is more likely to act as a monovalent reagent when excess amounts are present. Taken together, these data suggest that receptor crosslinking or aggregation is important in insulin action.
A possible role of microtubules and microfilaments in this aggregation might be suggested by effects on insulin binding of the various agents known to alter these structures (18) . However, pretreatment of cells with colchicine, vincristine, and vinblastine, agents which alter microtubular function (19) , at concentrations of 10 ,uM had no effect on basal, insulin-stimulated, or antibody-stimulated glucose oxidation ( Table 1) . As previously described, cytochalasin B, an antimicrofilament agent (20) , at 1 ,g/ml lowers basal glucose oxidation (transport) control -basal The data are presented as the mean ± SEM for three experiments, each done in triplicate. The increase in glucose oxidation observed with anti-insulin antibody at a dilution of 1:3 X 106 is significant at the p < 0.05 level. Anti-insulin antibody alone produced no systematic change in glucose oxidation (data not shown). (23, 24) . Almost no clues exist as to the nature of the transmembrane signal itself. A possible role for movement of receptors in the plane of the membrane has been suggested by the finding that insulin receptors appear to be clustered (25, 26) , and a temperature-dependent delay in the onset of insulin action has been noted (27) . Using fluorescent derivatives of insulin, Schlessinger et al. (28) have shown that insulin on fibroblasts can move laterally with a diffusion coefficient (3-5 X 10-10 cm2/sec) similar to that for other mobile membrane proteins.
In 1975 we discovered that sera of some patients with insulin-resistant diabetes contain autoantibodies to the insulin receptor (6, 7, 29) and this has provided new probes for the study of insulin action. These antibodies, which were initially found by their ability to inhibit insulin binding to its receptor (6) , also produce insulin-like biological effects when exposed to tissues in vitro (10, 11) . By using both adipocytes and isolated soleus muscle, we and others have shown that these antibodies stim-ulate glucose transport, glucose incorporation into glycogen and lipid, and glucose metabolism to CO2. In addition, antireceptor antibodies stimulate amino acid transport (30) and mimic the antilipolytic effect of insulin (30, 31) . In collaboration with J. Lawrence and J. Larner, we have found that these antibodies will also inhibit phosphorylase activity and activate glycogen synthase both in the presence and in the absence of glucose, two changes in activity of cytoplasmic enzymes characteristic of insulin action (unpublished data).
Although many other factors, such as lectins (32) and polyamines (33) , have been shown to mimic some of insulin's actions, only the antireceptor antibody appears equipotent with insulin, and in contrast to many of these other agents, its bioeffects seem to be due to direct and specific interaction with the insulin receptor. By using '25I-labeled antireceptor antibody, we have shown that these antibodies bind to cells in direct proportion to the concentration of insulin receptors and that the labeled antibody binding can be inhibited by insulin and insulin analogues in proportion to their affinity for the receptor (8) . In addition, the antireceptor antibodies will specificially immunoprecipitate solubilized insulin receptors*.
The facts that some of the compounds with insulin-likeractivity, such as lectins, are multivalent and that the antireceptor antibodies are bivalent suggested a possible role for receptor aggregation or crosslinking in insulin action. To test this, monovalent Fab' fragments of antireceptor IgG were prepared. Although these retained full ability to inhibit insulin binding, the monovalent antibody fragment lost almost all bioactivity. This change in bioactivity appears to be due to the change in valence rather than to the reduction and alkylation, because activity can be restored by crosslinking the monovalent Fab' with a second antibody (Fig. 5A ). In addition, Fab fragments produced by papain digestion without alkylation also lose bioactivity while retaining their ability to inhibit binding (F. A. Karlsson, K. L. Baird, and C. R. Kahn, unpublished observation) .
Although insulin in solution at concentrations at which it induces most of its biological responses is monomeric and presumably "monovalent," these observations, together with the previous findings that insulin receptors are mobile (28) or clustered (25, 26) , suggested a possible role for receptor aggregation or crosslinking in the action of insulin itself. To explore this possibility, we exposed cells to a submaximal dose of insulin and then to low concentrations of anti-insulin antibody (about 0.5-1.0 mol of antibody per mol of insulin). Under these circumstances anti-insulin antibodies actually enhanced insulin's effect, consistent with an effect of the insulin antibody to crosslink the insulin-receptor complexes (Fig. SB) .
Since all insulin analogues are agonists, presumably insulin is able to either initiate the biological response in the absence of receptor aggregation or induce receptor aggregation independent of external crosslinking (Fig. 5B) (34) . Interestingly, when insulin binds to the cell membrane, its local concentration may approach 10-6 M (J. Schlessinger, personal communication), a concentration at which insulin in solution dimerizes or aggregates (35) . Schlessinger et al. (36) have also shown that insulin on fibroblasts can form microscopically visible patches. If this aggregation is important for activity, however, it must differ from aggregation in solution, because there are several insulins which do not dimerize but are biologically active (35, 37) . Perhaps hagfish insulin, which has a lower bioactivity than affinity for the insulin receptor (38) , is unable to fully induce receptor aggregation. Proper orientation and spacing between the insulin monomers may also be important for the observed effect. Covalent insulin dimers linked by a short bridge between the A-I phenylalanine and the B-29 lysine have an activity which is approximately an average of the activities of the two chemically modified monomers (39) course, that the latter are required for some of the long-term growth stimulating effects of insulin. On the other hand, it is not clear if the latter effects are mediated via the insulin receptor or one of the receptors for the insulin-like growth factors.
The second major point is that "occupancy" of the receptor is not sufficient for signal generation. Thus, monovalent Fab' fragments of antireceptor antibody can "occupy" the insulin receptor, at least measured by their ability to block insulin binding and insulin action, without generating much insulinlike effect. A similar situation exists for the IgE receptor of the basophil in which crosslinking of receptors can be accomplished by IgE plus a second antibody, antibodies to the IgE receptor, or chemically crosslinked IgE dimers (41, 42) . Recently, Drachman et al. (43) , have shown that bivalency is also required for the accelerated receptor degradation produced by antibodies to the acetylcholine receptor from patients with myasthenia gravis. Whether a hormone such as insulin is able to induce receptor aggregation without external crosslinking or exerts its signal without receptor aggregation is unclear (34); however, some enhancement of the biological activity of insulin can be obtained by crosslinking insulin-receptor complexes under some circumstances. If aggregation does occur, neither microfilaments nor microtubules appear to be important. Whether some other membrane-associated proteins are required, however, is uncertain.
